78, P = .038; r = 0.69, P = .042, respectively; Figures 5A and 6A). Trastuzumab has been used

in the treatment of Her-2–positive metastatic breast cancer over one decade [4], [7] and [8]. Although it has great affinity for Her-2 and low toxicity, about 70% of patients do not respond to this treatment [12]. Therefore, early identification of patients who would benefit from trastuzumab can avoid additional cost for patients [6]. Traditional imaging and fluorescent in situ hybridization have been viewed as the “gold standard” techniques for predicting the treatment response, but they are expensive and not real-time systems [4], [13] and [14]. Our study intended to investigate the usage of ultrasound molecular imaging techniques to evaluate the response to trastuzumab learn more therapy in Her-2–positive breast cancer in the tumor xenograft high throughput screening compounds model. Dynamically monitoring the tumor inner change, such as tumor cell apoptosis during treatment, could be an early indicator of breast cancer response to trastuzumab [15]. An apoptosis marker, Annexin V, has been labeled with FITC and coupled to magnetic nanoparticles to identify apoptotic

cells [22] and [24]. In addition, there were various methods to design targeted apoptosis probes to detect tumor cell apoptosis. Previous studies used biotin/streptavidin interactions to conjugate targeting ligands, such as αvβ3 integrin, P-selectin, or vascular endothelial selleck products growth receptor 2, to image tumor angiogenesis,

or to evaluate the antiangiogenic therapy response of tumors [16], [17] and [18]. In our targeted apoptosis NB design, streptavidin-based bubbles binding to biotin–Annexin V were also used to dynamically detect tumor apoptotic cells during treatment in vitro and in vivo. These targeted bubbles with nanolevel diameters (less than 600 nm) can easily pass through the gaps between the tumor’s new microvascular endothelial cells (865 ± 5.2 nm, tested in the preparatory study) to adhere to the surface of tumor apoptotic cells in our tumor xenograft model. In the imaging study, we tested signals of NBs at 60 minutes after the injection. According to previous reports [17] and [19], it would be of enough time for bubbles to bind to tumor cells through vessels. Thus, it is possible for us to use these targeted NBs to detect tumor apoptotic cells in vivo. First, for seeking the binding ability of targeted NB with targeted cells in vitro, we found that NB–Annexin V bound to trastuzumab-treated cells significantly better than to control (buffer-treated) cells, which is confirmed by DAPI-stained nucleus test and caspase-3–positive expression. After preparing the breast cancer–bearing mice, we performed ultrasound targeted imaging to assess the early response to anti–Her-2 drugs in breast cancer.